PharmAla net loss narrows to CAD 499,759 in Q3 FY26; revenue more than doubled to CAD 513,000PUBT·10 hours agoJUNS-1.52%
Jupiter Neurosciences sells 11,470,000 shares to Yorkville for about $3.6 million in unregistered offeringPUBT·2 days ago, 04:21 PMJUNS-1.52%
Jupiter Neurosciences held annual shareholder meeting, with 59% of shares representedPUBT·Jul 27 at 08:03 AMJUNS-1.52%
Cross-Sector Divergence in 2026: How US Equities Navigate Global Macro HeadwindsGlobal Report·Jul 26 at 04:18 AMUAA-3.26%CHWY-2.06%
The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·Jul 26 at 04:14 AMINM-10.18%ONCY+0.19%
Strategic Recalibrations: Capital Shifts from Uranium Expansion to Digital OverhaulsGlobal Report·Jul 25 at 04:13 AMUEC+7.74%LASE+1.42%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·Jul 24 at 04:13 AMINM-10.18%TXG+6.71%
Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statementPUBT·Jul 22 at 08:13 PMJUNS-1.52%
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Jul 22 at 07:05 AMJUNS-1.52%INM-10.18%
Tech Pivots to Cloud Mega-Deals as AI Momentum Spills Into BiopharmaGlobal Report·Jul 22 at 04:17 AMAKAM+5.90%GENB+7.26%
Jupiter Neurosciences climbs 5% on $100M ALA-002 licensing dealUS Stock Market Update·Jul 21 at 02:40 PMJUNS-1.52%
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million | JUNS Stock NewsStockTitan·Jul 20 at 10:13 PMJUNS-1.52%
Jupiter Neurosciences jumps 4% on $100M drug licensing dealUS Stock Market Update·Jul 21 at 12:01 PMJUNS-1.52%
